A randomized, double-blind trial of efficacy and mechanism of Shiwei Yiyuan granules for cancer-related fatigue

Xiyuan Hospital of China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Pathologically confirmed primary lung cancer and colorectal cancer patients with measurable lesions can be evaluated for curative effect (Based on RECIST 1.1 therapeutic efficacy evaluation criteria for solid tumors);
•2.meet the diagnostic criteria for cancer-related fatigue;
•3. Fatigue Score >= 4.(The degree of fatigue was scored using a 0-10 numerical rating scale, 0 = no fatigue, 10 = most severe fatigue);
•4. Patients who agree not to participate in other intervention studies during treatment;
•5. Aged 18-80 years, regardless of gender;
•6. The estimated survival time is greater than 3 months.

•1. The patient who has severe bleeding or is systemically infected;
•2. The patient who has a clear invasion of bone marrow metastases;
•3. The patient who has received surgery, chemotherapy, radiotherapy, targeted therapy, immune or other anti-tumor therapy within 1 month;
•4. The patient who has used of erythropoietin and blood transfusion in the past 1 month;
•5. Patient with severe diseases of heart, liver, kidney and other systems;
•6. Pregnant women, lactating women, unconscious patients or patient who is unable to understand and participate in this study;
•7. As determined by the researcher, patient is not suitable to participate in this study.

发起方